Our findings provide substantial evidence that the upregulation of E2F8 plays an essential role in promoting ovarian cancer progression, and that E2F8 may represent a novel prognostic biomarker and therapeutic target for this disease. The gene discussed is E2F8; the disease is ovarian cancer.